Oxford BioMedica plc · LSE:OXB

Oxford BioMedica — H1 2017 Earnings Presentation

16 slides from Oxford BioMedica's earnings presentation, Aug 17, 2017

  1. Slide 1: The LentiVector Platform Company: Interim results six months ended 30 June 2017

    The LentiVector® Platform Company A leader in gene and cell therapy Interim results for six months ended 30 June 2017 17 August 2017

  2. Slide 2: Forward-looking statements

    Forward-looking statements This presentation does not constitute an offer to sell or a solicitation of offers to buy Ordinary Shares (the “Securities”). Although reasonable care has been taken to ensure that the facts stated in this presentation are accurate and that the opinions 2 Cohort expressed

  3. Slide 3: Operational highlights

    Operational highlights • Novartis collaboration progressing well • MHRA licence granted for Group’sMean lentiviral vector manufacture and supply Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) 1, n=3 1x Original 27% Mean 30% Mean 29% Mean 20% Max. up to 3

  4. Slide 4: Novartis partnership progress since March 2017

    Novartis partnership progress since March 2017 • Biologic Licence Application – CTL019 • March 2017 – FDA accepted BLA filing for paediatric ALL Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) • July 2017 – FDA ODAC voted unanimously in favour 1, n=3 1x O

  5. Slide 5: LentiVector platform

    LentiVector® platform • Regulatory approvals • FDA pre-licence inspection as part of CTL019 BLA process • Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) MHRA licence to manufacture and distribute lentiviral vector material for commercial 1, n=3 Mean 27%

  6. Slide 6: Business development – extensive lentiviral vector clinical/pre-clinical trial activity

    Business development – extensive lentiviral vector clinical/pre-clinical trial activity Cohort2 1, n=3 ✓Dose 1x Administration Original 3 months (UPDRS) Mean 27% ✓ 6 months (UPDRS) Mean 30% 1 year (UPDRS) Mean 29% 2 years (UPDRS) Mean 20% ✓ Max. up to 30% Max. up to 50% Max. up to 44% Max. up to 30%

  7. Slide 7: In-house development pipeline

    In-house development pipeline • Continuing to prepare priority programmes (OXB-102, OXB-202, OXB-302) for clinical studies Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) 1, n=3 1x Original Mean 27% Mean 30% Mean 29% Mean 20% Max. up to 30% Max. up to 50%

  8. Slide 8: Product pipeline

    Product pipeline Product Indication Pre-Clinical Phase I Phase I/II Phase II Phase III Approval OXB Proprietary Products OXB-102 Cohort2 Parkinson’s Dose disease Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) OXB-202 1, n=3 Corneal 1xgraft rejection Original Mean 27%

  9. Slide 9: Financial review

    Financial review

  10. Slide 10: Financial highlights

    Financial highlights • Revenue increased by 26% to £15.7 million (H1 2016: £12.5 million) Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) •1, n=3Operating1x loss reduced Original Mean 27% to £2.2 million Mean 30% (H1 2016: Max. up to 30% Mean 29% £6.9 mil

  11. Slide 11: Gross income and EBIDA

    Gross income1 and EBIDA2 Gross income (£m) 20 Includes £6.1m Cohort2 Dose Novartis upfronts Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) Licences, 2 years (UPDRS) 15 incentives, 1, n=3 1x Original Mean 27% Mean 30% Mean 29% Mean 20% Max. up to 30% Max. up to 50% Max. up to 44% gra

  12. Slide 12: Segmental analysis

    Segmental analysis Partnering segment (£m) R&D segment (£m) H1 2016 H2 2016 H1 2017 H1 2016 H2 2016 H1 2017 Cohort2 18 Dose Administration 3 months (UPDRS) 2 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) 16 1, n=3 1x Original Mean 27% 1 Mean 30% Mean 29% Mean 20% Max. up to 30% Max. up to 50% Max.

  13. Slide 13: Potential catalysts over next 12 months

    Potential catalysts over next 12 months • Novartis progress • FDA approval of CTL0191 for r/r ALL and product launch Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) 1, n=3 • Submission 1x of DLBCL for approval Original Mean 27% Mean 30% Mean 29% Mean 20%

  14. Slide 14: Vision of Oxford BioMedica – by end of 2018

    Vision of Oxford BioMedica – by end of 2018 Core LentiVector® Product pipeline Bioprocessing Core LentiVector ® R&D Bioprocessing platform R&D Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) OXB-102 Facilities operating at, operating Facilities 1, n=3 pro

  15. Slide 15: Summary: a leading gene and cell therapy company

    Summary: a leading gene and cell therapy company • Gene and cell therapy is predicted to grow into a multi-billion US$ sector Cohort2 Dose 1 over the next 5-10 Administration years 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) 1, n=3 1x Original Mean 27% Mean 30% Mean 29% Mean 20%

  16. Slide 16: Contact Us

    Contact Us Oxford BioMedica plc Windrush Court Transport Way Oxford OX4 6LT John Dawson, CEO Tim Watts, CFO Tel: +44 (0) 1865 783 000 enquiries@oxfordbiomedica.co.uk www.oxfordbiomedica.co.uk

Oxford BioMedica — H1 2017 Earnings Presentation on 6ix